Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment (statin or combination) reaching the LDL-C goals according to the updated 2004 National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines.

Detailed Description
-----------------
MC MD

Official Title
-----------------
Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes

Conditions
-----------------
Dyslipidemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Provision of subject informed consent, Female or male aged = 18 years Patients eligible for treatment of dyslipidemia with statins, according to the current guidelines NCEP ATPIII about Dyslipidemias and Atherosclerosis Prevention Receiving lipid-lowering drug treatment for at least 15 days. Exclusion Criteria: Involvement in the planning and conduct of the study (applies to either AstraZeneca staff or staff at the study site). Previous enrolment or randomisation of treatment in the present study Participation in a clinical study during the last 90 days

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number (#) of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP III guidelines. |  | 1 year | 
| The percent (%) of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP III guidelines. |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for several subject subsets |  | 1 year | 
| The number of the secondary event rate of cerebrovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 |  | 1 year | 
| The number of the secondary event rate cardiovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 year |  | 1 year | 
| The percentage of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for several subject subsets |  | 1 year | 
| The percent of the secondary event rate of cerebrovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 |  | 1 year | 
| The percent of the secondary event rate cardiovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 year |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dyslipidemia Treatment and Cardiovascular Outcomes